Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States ...Middle East

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive global rights to develop, commercialize, and manufacture ATG-017 - The combination portion of the ERASER study, the first-in-human (FIH) study of ATG-017, was designed to evaluate the...

Hence then, the article about antengene announces first patient dosed in the nivolumab combination portion of the clinical study evaluating the erk1 2 inhibitor atg 017 in patients with advanced solid tumors in the united states was published today ( Tuesday 18/07/2023 - 03:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States )

Also on site :

• What to Know About Allegations of Excessive Drinking by FBI Director Kash Patel
• Gunman opens fire and seizes supermarket in Kiev (VIDEOS)
• Astros Claim Dustin Harris, Designate J.P. France For Assignment